Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Monoclonal antibody against claudin-18 for the treatment of cancer

一种癌症、蛋白的技术，应用在用于治疗癌症的针对密蛋白-18的单克隆抗体领域，能够解决抗体无法接近等问题

Active Publication Date: 2018-06-29
ASTELLAS PHARMA INC +1
View PDF48 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is possible that in healthy epithelium the binding epitope of claudin is shielded in tight junctions, making it inaccessible to these antibodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal antibody against claudin-18 for the treatment of cancer
  • Monoclonal antibody against claudin-18 for the treatment of cancer
  • Monoclonal antibody against claudin-18 for the treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0435] 1. Generation of mouse antibodies against CLD18

[0436] a. Immunity:

[0437] Balb / c or C57 / BL6 mice were immunized with eukaryotic expression vectors encoding human CLD18 fragments (SEQ ID NO: 15, 16, 17, 18). In the presence of an adjuvant (such as CpG), 50 μg or 25 μg of plasmid DNA was injected into the quadriceps muscle (intramuscular, i.m.) on days 1 and 10 for the production of group 1 monoclonal antibodies, or on day 1 Day 1 and day 9, day 1 and day 11 or day 1, day 16 and day 36 for generation of a second set of antibodies (see Table 1b for details). CpG was injected intramuscularly along with cells transfected with CLD18A2 (SEQ ID NO: 1 ) alone or co-transfected with CLD18A2 and mouse soluble CD40L encoding RNA, PEI-Man was injected intramuscularly or intraperitoneally. Depending on the specific immunization protocol used, mouse sera were monitored for the presence of antibodies against human CLD18 by immunofluorescence microscopy between days 16 and 43. I...

example

[0486] The binding specificity of the identified mAbs to the CLD18A2 isoform was analyzed by flow cytometry. HEK293 cells stably expressing human CLD18A2 (HEK293-CLD18A2) and HEK293 cells stably expressing human CLD18A1 (SEQ ID NO: 7, 8) (HEK293-CLD18A1) were incubated with hybridoma supernatants containing monoclonal antibodies at 4°C After 30 minutes incubation with Alexa647-conjugated anti-mouse IgG secondary antibody and cells fixed or left unfixed and counterstained with PI. Binding was assessed by flow cytometry using a BD FACSArray. Figure 6 shows the Examples of two groups of mAbs identified in 175D10: (i) mAbs 43A11, 45C1 and 163E12 specifically bind human CLD18A2, but not human CLD18A1 ( Figure 6A , B), and (ii) mAb 37H8 binds to both human isoforms ( Figure 6A ).

[0487] e. Comparison of antibody binding to human CLD18A1 and CLD18A2 transfectants by immunofluorescence microscopy:

[0488] HEK293 cells were transiently transfected with an expression vector en...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides antibodies that can be used as therapeutic agents for the treatment and / or prevention of diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, Liver, head and neck and gallbladder cancers.

Description

[0001] This application is a divisional application of a Chinese patent application with an application date of November 24, 2006, an application number of "200680043664.X", and an invention title of "a monoclonal antibody against claudin-18 for the treatment of cancer". The original application was a Chinese national phase application of the international application PCT / EP2006 / 011302. technical field [0002] Antibody-based cancer therapies have the potential for higher specificity and lower side effect profiles than conventional drugs. This is due to the antibody's precise distinction between normal and neoplastic cells and the fact that its mode of action relies on less toxic immunological anti-tumor mechanisms, such as complement activation and recruitment of cytotoxic immune cells. Background technique [0003] Targets for antibody-based therapies must have specific properties, which form the basis for the correct distinction between normal and neoplastic cells. Clear...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/30C12N5/20C12N5/09A61K39/395A61P35/00C12R1/91
CPCA61K51/1063C07K16/3046C07K2317/73C07K2317/732C07K2317/734A61K47/6813A61K47/6821A61K47/6823A61K47/6829A61K47/6863A61K47/6809A61K47/6803A61P35/00A61P35/04A61P43/00A61K39/395C07K16/30A61K47/50A61K47/6851A61K47/6807A61K47/6859A61K39/3955A61K45/06A61K2039/505C07K16/18C07K2317/14C07K2317/24C07K2317/56C07K2317/51C07K2317/515C07K2317/565C07K16/28C07K2317/76A61K47/6869
Inventor 乌尔·沙欣厄兹莱姆·图雷奇迪尔克·乌泽纳斯特凡·弗里茨克里斯托夫·乌赫雷克贡达·勃兰登堡哈拉尔德-格哈德·格佩特安雅·克里斯蒂娜·施罗德菲利普·蒂尔
Owner ASTELLAS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com